Drug Combo Shows Benefits in Fit Patients With Acute Myeloid Leukemia

(MedPage Today) — ORLANDO — Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction chemotherapy, a phase II…